Regeneron, Parabilis Ink Up-to-$2.3B Antibody-Peptide Conjugate Collaboration

Regeneron will marry its antibody capabilities with Parabilis’ stabilized helical peptide or Helicon™ platform, with the goal of developing both Antibody-Helicon™ Conjugates (AHCs) as well as stand-alone therapies based on Helicons—stabilized, cell-penetrant alpha-helical peptides designed to engage intracellular protein targets, including flat surfaces that are not well suited to traditional small molecule binding. The post Regeneron, Parabilis Ink Up-to-$2.3B Antibody-Peptide Conjugate Collabo...